Anixa Biosciences Inc Stock Price, News & Analysis

Anixa Biosciences has completed enrollment in its Phase 1 breast cancer vaccine trial, developed in partnership with Cleveland Clinic and funded by the Department of Defense. The trial enrolled 35 participants across three cohorts: 26 triple-negative breast cancer survivors at risk of recurrence, 4 high-risk individuals undergoing preventative mastectomy, and 5 patients receiving pembrolizumab treatment. Preliminary results show over 70% of patients demonstrating protocol-defined immune responses, with the vaccine being well-tolerated. The final patient visits are scheduled for August 2025, after which results will be submitted to the DoD and FDA. The vaccine targets a novel pathway in immuno-oncology and aims to address unmet needs in breast cancer prevention and treatment, particularly for TNBC and genetically high-risk populations.

Anixa Biosciences (NASDAQ: ANIX) CEO provided a shareholder update highlighting significant progress in their cancer treatment programs. The company maintains strong financial health with $17 million in cash, no debt, and a low annual burn rate of $7 million. Their CAR-T therapy program for ovarian cancer has completed three dose-escalation cohorts, with encouraging survival data in early trials. The breast cancer vaccine program, developed with Cleveland Clinic, is nearing Phase 1 completion with over 70% of patients showing immune responses. The vaccine targets three groups: triple-negative breast cancer survivors, high-risk individuals, and patients with residual disease. Key upcoming milestones include final Phase 1 data presentation at the San Antonio Breast Cancer Symposium in December 2025, FDA interactions for Phase 2, and initiation of Cohort 4 for the CAR-T program.

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Pamela D. Garzone will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3, 2025. The presentation will focus on the company's Phase 1 clinical trial of their ovarian cancer CAR-T immunotherapy.

The poster, led by Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator of the trial, will discuss the study of autologous T-cells genetically engineered to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The presentation is scheduled for June 2, 2025, from 1:30 PM to 4:30 PM CT.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference.

The conference will take place on May 20, 2025, at the Nasdaq World Headquarters in New York City. Mike Catelani, who serves as President and CFO of Anixa, will deliver a presentation at 11:00 AM ET and will be available for one-on-one meetings throughout the conference.

Interested parties can access the presentation through a webcast link provided by the company. This investor conference appearance represents an opportunity for Anixa to showcase its developments in cancer-focused biotechnology to the investment community.

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology. The allowed claims encompass core methods and compositions fundamental to Anixa's innovative CAR-T approach, which is specifically designed to address challenges in applying CAR-T therapies to solid tumors.

The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. The company's CAR-T technology is currently being tested in a clinical trial at Moffitt Cancer Center for treating recurrent ovarian cancer patients.

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, expands the scope of immunogenic compositions in Anixa's breast cancer vaccine development.

The newly allowed patent specifically covers methods of immunizing patients against breast cancer through the administration of an immunogenic composition containing the human α-lactalbumin protein. This protein is typically expressed during lactation in breast tissue and in certain breast cancers, making it a strategic target for immunoprevention approaches.

Anixa Biosciences (NASDAQ: ANIX), a biotechnology company specializing in cancer treatment and prevention, has announced its participation in the upcoming Jones Las Vegas Healthcare and Technology Innovation Conference. The event will take place on April 8-9, 2025, at The Venetian Resort in Las Vegas.

Mike Catelani, President and CFO of Anixa, is scheduled to present on April 9, 2025, at 4:30 PM PT. The presentation will be accessible via webcast, and Catelani will be available for one-on-one meetings throughout the conference.

The two-day conference, organized by Jones with B2i Digital's marketing support, will facilitate direct interactions between company executives and institutional investors through various formats including one-on-one meetings, fireside chats, panels, presentations, and networking events.

Anixa Biosciences (NASDAQ: ANIX) has entered into a letter of intent with VERDI Solutions to develop AI-guided personalized and off-the-shelf peptide vaccines for cancer patients. VERDI's cloud-computing platform enables rapid development of personalized vaccines tailored to individual cancer patients.

The agreement grants Anixa a six-month exclusive right to negotiate the research, development, and commercialization of VERDI's cancer vaccines. VERDI has already demonstrated success in three patients with bone metastases under Europe's Individueller Heilversuch program, where patients experienced clinical benefits including significant pain relief and improved quality of life.

VERDI's proprietary algorithm predicts vaccine efficacy in recognizing and eliminating tumor cells at an individual level. While VERDI continues developing personalized vaccines in Europe, both companies plan to initiate clinical trials in the United States.

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a key patent application covering its ovarian cancer vaccine technology. The patent includes broad claims related to methods of eliciting an immune response targeting Anti-Mullerian Hormone Receptor, Type II (AMHR2), which is considered a promising target for ovarian cancer prevention and treatment.

The vaccine, being developed in collaboration with Cleveland Clinic and the National Cancer Institute, represents a novel approach particularly focused on high-risk populations, including individuals with BRCA mutations or family history of ovarian cancer. The allowed claims specifically cover methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide's extracellular domain to elicit an AMHR2-specific immune response.